NEB and nemaline myopathy: While it has been recently suggested that Ca2+ sensitizers agents might counterbalance muscle weakness [40] in NM patients carrying mutation in the NEB gene [22], our data indicated that these pharmaceutical agents would be ineffective for counteracting the deleterious effects of H40Y mutation on muscle function.